Takeda puts forward new bid for Shire

Takeda has put forward a new bid for Shire, increasing the cash portion of the deal.
Based on Takeda’s current market capitalisation, Shire’s shareholders would own around 49% of the new group.
The new bid proposal represents a premium of around 58%, replacing an earlier offer of £28.75 per share, and £17.75 per share in cash.
Takeda believe the new proposal would mean that Shire shareholders would hold a meaningful stake in a leading global biopharmaceutical company, and it represents an opportunity which will reflect an increase in value and a material increase in the cash component of the consideration mix.
Shire’s board is now considering its position and will make an announcement in due course.